| Checkpoint blocking antibodies in cancer immunotherapy C Kyi, MA Postow FEBS letters 588 (2), 368-376, 2014 | 360 | 2014 |
| The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma M Del Castillo, FA Romero, E Argüello, C Kyi, MA Postow, ... Clinical Infectious Diseases 63 (11), 1490-1493, 2016 | 313 | 2016 |
| Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges C Kyi, MA Postow Immunotherapy 8 (7), 821-837, 2016 | 177 | 2016 |
| Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial RL Ferris, WC Spanos, R Leidner, A Gonçalves, UM Martens, C Kyi, ... Journal for immunotherapy of cancer 9 (6), e002568, 2021 | 157 | 2021 |
| Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients S Kitano, T Tsuji, C Liu, D Hirschhorn-Cymerman, C Kyi, Z Mu, JP Allison, ... Cancer immunology research 1 (4), 235-244, 2013 | 145 | 2013 |
| Therapeutic immune modulation against solid cancers with intratumoral poly-ICLC: a pilot trial C Kyi, V Roudko, R Sabado, Y Saenger, W Loging, J Mandeli, TH Thin, ... Clinical Cancer Research 24 (20), 4937-4948, 2018 | 127 | 2018 |
| Opportunistic infections in patients treated with immunotherapy for cancer C Kyi, MD Hellmann, JD Wolchok, PB Chapman, MA Postow Journal for immunotherapy of cancer 2, 1-3, 2014 | 126 | 2014 |
| Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525)±anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies P Schöffski, DSW Tan, M Martín, M Ochoa-de-Olza, J Sarantopoulos, ... Journal for immunotherapy of cancer 10 (2), e003776, 2022 | 125 | 2022 |
| Ipilimumab in patients with melanoma and autoimmune disease C Kyi, RD Carvajal, JD Wolchok, MA Postow Journal for immunotherapy of cancer 2, 1-4, 2014 | 99 | 2014 |
| Phase I/II study of LAG525±spartalizumab (PDR001) in patients (pts) with advanced malignancies. DS Hong, P Schoffski, A Calvo, J Sarantopoulos, M Ochoa De Olza, ... Journal of Clinical Oncology 36 (15_suppl), 3012-3012, 2018 | 76 | 2018 |
| Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint … P Friedlander, K Wassmann, AM Christenfeld, D Fisher, C Kyi, ... Journal for ImmunoTherapy of Cancer 5, 1-9, 2017 | 42 | 2017 |
| A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma. MM Rubinstein, I Caird, Q Zhou, A Iasonos, CF Friedman, KA Cadoo, ... Journal of Clinical Oncology 37 (15_suppl), 5582-5582, 2019 | 33 | 2019 |
| A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results AR Rappaport, C Kyi, M Lane, MG Hart, ML Johnson, BS Henick, CY Liao, ... Nature medicine 30 (4), 1013-1022, 2024 | 31 | 2024 |
| Gastric-type adenocarcinoma of the cervix: clinical outcomes and genomic drivers S Ehmann, D Sassine, AM Straubhar, AM Praiss, C Aghajanian, ... Gynecologic oncology 167 (3), 458-466, 2022 | 28 | 2022 |
| Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy C Kyi, CF Friedman, JJ Mueller, R Benayed, M Ladanyi, M Arcila, ... Gynecologic Oncology Reports 37, 100852, 2021 | 22 | 2021 |
| Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res. 2013; 1 (4): 235–244. doi: 10 … S Kitano, T Tsuji, C Liu, D Hirschhorn-Cymerman, C Kyi, Z Mu, JP Allison, ... CIR-13-0068, 0 | 21 | |
| 387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies CC Lin, E Garralda, P Schöffski, D Hong, L Siu, M Martin, M Maur, R Hui, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | 15 | 2020 |
| A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies CC Lin, E Garralda, P Schöffski, DS Hong, LL Siu, M Martin, M Maur, ... Oncoimmunology 13 (1), 2290787, 2024 | 14 | 2024 |
| Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study MM Rubinstein, ER Doria, J Konner, S Lichtman, Q Zhou, A Iasonos, ... Gynecologic oncology 169, 64-69, 2023 | 14 | 2023 |
| A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers MM Rubinstein, RN Grisham, K Cadoo, C Kyi, WP Tew, CF Friedman, ... Gynecologic oncology 160 (1), 71-76, 2021 | 14 | 2021 |
